The Current Gap
Acute Myeloid Leukemia (AML) remains a challenging disease with poor long-term outcomes despite significant advancements in treatment.
While new therapies, such as FLT3 inhibitors and venetoclax-based regimens, have improved initial response rates, durable remissions and long-term survival remain elusive, particularly for older or unfit patients who cannot tolerate intensive chemotherapy or stem cell transplants ...
Our Breakthrough approach
Cycuria Therapeutics is revolutionizing blood cancer treatment with its proprietary engineered cytokines.
Our approach directly and specifically targets leukemic cells and their progenitor stem cells, while preserving healthy blood formation and minimizing systemic toxicity...
High incidence rate for AML,
specially in >60 yrs population
in every 100.000
Poor Overall survival rate
for AML patients
3-year survival rate
TEAM
Our experienced management team brings deep expertise in cytokine biology, protein engineering, clinical hemato-oncology and early-stage drug discovery and development
Prof. Dr. Philipp J. Jost
Inventor, Co-Founder & CSO
Dr. Nisit Khandelwal
Co-Founder & CEO
Prof. Dr. Felix Wieland
Directorem. Uni Heidelberg (BZH)
Prof. Dr. Walter Nickel
Managing DirectorofBZH, Uni Heidelberg
Our Blog
Latest CYCURIA News
Meet Cycuria at ASH Annual Meeting 2024 in San Diego
Cycuria will be attending the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego from December 7- December 10. We look forward to
Cycuria Founder, Prof. Dr. Philipp Jost, Highlights the Strategic Advantages and Opportunities at Medical Science City Graz
We’re thrilled to share recent press coverage highlighting Cycuria Therapeutics‘ innovative approach in oncology and our choice to establish roots in Graz’s Medical Science City,
Cycuria Featured in the Austrian National Newspaper Die Presse
Die Presse, one of Austria’s most respected national newspapers, features our scientific breakthrough in cancer research led by our scientific founder, Prof. Dr. Philipp Jost.
Contact Us
Cycuria Therapeutics
Center for Knowledge Transfer II (ZWT II)
Medical Science City Graz
Stiftingtalstraße 14
8010 Graz
Austria